Retina Health Market Research Reportβ€”Global Forecast till 2030

Retina Health Market: Information by Treatment (Drugs, Therapy, and Surgery), by Disease Indication (Age-Related Macular Degeneration, Diabetic Retinopathy, Inherited Retinal Diseases, Retinoblastoma, and Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)β€”Forecast till 2030

ID: MRFR/HC/9429-CR | August 2022 | Region: Global | 141 Pages         

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING PREVALENCE OF RETINAL DISEASES ACROSS THE GLOBE

4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES

4.3 RESTRAINTS

4.3.1 LACK OF AWARENESS REGARDING RETINAL DISEASES

4.4 OPPORTUNITY

4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING RETINAL DISEASES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE RETINA HEALTH MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON PRODUCTION

5.3.3 IMPACT ON MARKET PLAYERS

5.3.4 IMPACT ON DEMAND

6 GLOBAL RETINA HEALTH MARKET, BY TREATMENT

6.1 OVERVIEW

6.2 DRUGS

6.3 THERAPY

6.3.1 GENE THERAPY

6.3.2 NUTRITION THERAPY

6.3.3 OTHERS

6.4 SURGERY

7 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION

7.1 OVERVIEW

7.2 AGE-RELATED MACULAR DEGENERATION

7.3 DIABETIC RETINOPATHY

7.4 INHERITED RETINAL DISEASES

7.5 RETINOBLASTOMA

7.6 OTHERS

8 GLOBAL RETINA HEALTH MARKET, BY REGION

8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 GERMANY

8.3.2 UK

8.3.3 FRANCE

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA-PACIFIC

8.4.1 JAPAN

8.4.2 CHINA

8.4.3 INDIA

8.4.4 AUSTRALIA

8.4.5 SOUTH KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 REST OF THE WORLD

8.5.1 MIDDLE EAST

8.5.2 AFRICA

8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL RETINA HEALTH MARKET

9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL RETINA HEALTH MARKET

9.5 KEY DEVELOPMENT ANALYSIS

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL

9.6.2 MERGER & ACQUISITIONS

9.6.3 EXPANSION

9.6.4 AGREEMENT/MARKETING STRATEGIES

9.7 FINANCIAL MATRIX

9.7.1 SALES (USD MILLION), 2021

9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

10.1 NOVARTIS AG

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS/SERVICES OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 SPARK THERAPEUTICS, INC.

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS/SERVICES OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 KEY STRATEGIES

10.3 GENSIGHT BIOLOGICS

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS/SERVICES OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 ALLERGAN PLC (SUBSIDIARY OF ABBVIE INC.)

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS/SERVICES OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 SWOT ANALYSIS

10.4.6 KEY STRATEGIES

10.5 OXFORD BIOMEDICA PLC

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS/SERVICES OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 HEMERA BIOSCIENCES LLC

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS/SERVICES OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 SANTEN PHARMACEUTICALS INC.

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 REGENXBIO INC.

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 SWOT ANALYSIS

10.8.6 KEY STRATEGIES

10.9 MEIRAGTX LIMITED

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC)

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

 

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 4 COMMON RETINA DRUGS

TABLE 5 GLOBAL RETINA HEALTH MARKET, FOR DRUGS, BY REGION, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL RETINA HEALTH MARKET, FOR THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL RETINA HEALTH MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL RETINA HEALTH MARKET, FOR GENE THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL RETINA HEALTH MARKET, FOR NUTRITION THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL RETINA HEALTH MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL RETINA HEALTH MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL RETINA HEALTH MARKET, FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL RETINA HEALTH MARKET, FOR DIABETIC RETINOPATHY, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL RETINA HEALTH MARKET, FOR INHERITED RETINAL DISEASES, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL RETINA HEALTH MARKET, FOR RETINOBLASTOMA, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL RETINA HEALTH MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL: RETINA HEALTH MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 19 NORTH AMERICA: RETINA HEALTH MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 20 NORTH AMERICA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 21 NORTH AMERICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 22 NORTH AMERICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 23 US: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 24 US: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 25 US: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 26 CANADA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 27 CANADA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 28 CANADA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 29 EUROPE: RETINA HEALTH MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 30 EUROPE: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 31 EUROPE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 32 EUROPE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 33 GERMANY: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 34 GERMANY: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 35 GERMANY: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 36 UK: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 37 UK: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 38 UK: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 39 FRANCE: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 40 FRANCE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 41 FRANCE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 42 ITALY: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 43 ITALY: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 44 ITALY: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 45 SPAIN: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 46 SPAIN: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 47 SPAIN: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 48 REST OF EUROPE: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 49 REST OF EUROPE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 50 REST OF EUROPE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC: RETINA HEALTH MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 55 JAPAN: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 56 JAPAN: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 57 JAPAN: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 58 CHINA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 59 CHINA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 60 CHINA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 61 INDIA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 62 INDIA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 63 INDIA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 64 AUSTRALIA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 65 AUSTRALIA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 66 AUSTRALIA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 67 SOUTH KOREA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 68 SOUTH KOREA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 69 SOUTH KOREA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 70 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 71 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 72 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 73 REST OF THE WORLD: RETINA HEALTH MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 74 REST OF THE WORLD: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 75 REST OF THE WORLD: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 76 REST OF THE WORLD: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 77 MIDDLE EAST: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 78 MIDDLE EAST: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 79 MIDDLE EAST: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 80 AFRICA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 81 AFRICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 82 AFRICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 83 LATIN AMERICA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 84 LATIN AMERICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 85 LATIN AMERICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 86 MAJOR PLAYERS IN THE GLOBAL RETINA HEALTH MARKET

TABLE 87 MOST ACTIVE PLAYERS IN THE GLOBAL RETINA HEALTH MARKET

TABLE 88 PRODUCT LAUNCH/PRODUCT APPROVAL

TABLE 89 MERGER & ACQUISITIONS

TABLE 90 EXPANSION

TABLE 91 AGREEMENT/MARKETING STRATEGIES

TABLE 92 NOVARTIS AG: PRODUCTS OFFERED

TABLE 93 NOVARTIS AG: KEY DEVELOPMENTS

TABLE 94 SPARK THERAPEUTICS, INC.: PRODUCTS/SERVICES OFFERED

TABLE 95 SPARK THERAPEUTICS, INC.: KEY DEVELOPMENTS

TABLE 96 GENSIGHT BIOLOGICS: PRODUCTS OFFERED

TABLE 97 ALLERGAN PLC: PRODUCTS/SERVICES OFFERED

TABLE 98 ALLERGAN PLC: KEY DEVELOPMENTS

TABLE 99 OXFORD BIOMEDICA PLC: PRODUCTS/SERVICES OFFERED

TABLE 100 HEMERA BIOSCIENCES LLC: PRODUCTS/SERVICES OFFERED

TABLE 101 HEMERA BIOSCIENCES LLC: KEY DEVELOPMENTS

TABLE 102 SANTEN PHARMACEUTICALS INC.: PRODUCTS OFFERED

TABLE 103 SANTEN PHARMACEUTICALS INC.: KEY DEVELOPMENTS

TABLE 104 REGENXBIO INC.: PRODUCTS OFFERED

TABLE 105 REGENXBIO INC.: KEY DEVELOPMENTS

TABLE 106 MEIRAGTX LIMITED: PRODUCTS OFFERED

TABLE 107 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC): PRODUCTS OFFERED

 

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL RETINA HEALTH MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL RETINA HEALTH MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINTS IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL RETINA HEALTH MARKETMARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL RETINA HEALTH MARKET

FIGURE 9 GLOBAL RETINA HEALTH MARKET, BY TREATMENT, 2021 & 2030 (USD MILLION)

FIGURE 10 GLOBAL RETINA HEALTH MARKET SHARE, BY TREATMENT (%), 2021

FIGURE 11 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION, 2021 & 2030 (USD MILLION)

FIGURE 12 GLOBAL RETINA HEALTH MARKET SHARE, BY DISEASE INDICATION (%), 2021

FIGURE 13 GLOBAL: RETINA HEALTH MARKET, BY REGION 2021 & 2030 (USD MILLION)

FIGURE 14 GLOBAL: RETINA HEALTH MARKET SHARE, BY REGION 2021 (%)

FIGURE 15 NORTH AMERICA: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)

FIGURE 16 EUROPE: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)

FIGURE 17 ASIA-PACIFIC: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)

FIGURE 18 REST OF THE WORLD: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)

FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL RETINA HEALTH MARKET

FIGURE 21 GLOBAL RETINA HEALTH MARKET: COMPETITIVE LANDSCAPE

FIGURE 22 SALES (USD MILLION), 2021

FIGURE 23 RESEARCH & DEVELOPMENT EXPENDITURE 2021

FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 NOVARTIS AG: SWOT ANALYSIS

FIGURE 26 ALLERGAN PLC: SWOT ANALYSIS

FIGURE 27 OXFORD BIOMEDICA PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 HEMERA BIOSCIENCES LLC: SWOT ANALYSIS

FIGURE 29 SANTEN PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 SANTEN PHARMACEUTICALS INC.: SWOT ANALYSIS

FIGURE 31 REGENXBIO INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 REGENXBIO INC.: SWOT ANALYSIS

FIGURE 33 MEIRAGTX LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC): FINANCIAL OVERVIEW SNAPSHOT

Retina Health Market

Retina Health Market is expected to reach USD 24.22 billion by 2030 at a CAGR of 7.01% during the forecast period

Segmentation

By Treatment Drugs Therapy Surgery
By Disease Indication Age Related Macular Degeneration Diabetic Retinopathy Inherited Retinal Diseases Retinoblastoma

Key Players

  • Novartis AG
  • Spark Therapeutics
  • Gensight Biologics
  • Allergan Plc
  • Oxford Biomedica Plc
  • Hemera Biosciences LLC
  • Santen Pharmaceuticals Inc
  • Regenxbio Inc
  • Meiragtx Limited

Drivers

  • Growing prevalence of retinal diseases across the globe
  • Rising number of strategic initiatives
Speak to Analyst Request a Free Sample

Retina Health Market Overview:


The retina health market size is expected to reach USD 24.22 billion by 2030 and register a CAGR of 7.01% during the forecast period of 2022 to 2030. Retina refers to the thin layer present at the back of the eye which is responsible for the conversion of the light that enters the eye into electrical signals that can be processed into images by the brain. A healthy retina is essential for the prevention of vision impairments and even blindness. Macular degeneration and diabetic retinopathy are two common major retinal disorders affecting millions across the globe. The growth of the global retina health market is attributed to the growing prevalence of retinal diseases across the globe, and the rising number of strategic initiatives. Furthermore, increasing initiatives by public and private organizations to drive awareness regarding retinal diseases is expected to create lucrative growth opportunities for the market in the forecast period. However, the lack of awareness regarding retinal diseases is anticipated to hamper the market growth.


Impact of COVID-19


The pandemic has affected the business landscape for many organizations around the world. The supply chain in the retina health market is the key to fulfilling customer demands. As a result of the pandemic, several countries-imposed import and export restrictions. This also affected the healthcare industry as certain nations rely on others for raw material supply and technology. The COVID-19 had a negative impact on production of retina health globally in 2020. This was due to international trade restrictions and border closures which significantly impacted the supply chain of the market. For instance, US relies heavily on China and India for procurement of ingredients and final products for ophthalmic products. Moreover, the trade restrictions and manufacturing interruptions caused by the pandemic affected the retina health product manufacturing as well. Moreover, Key companies such as Novartis (Switzerland), Bausch Health Companies Inc. (Canada), Alcon (Switzerland), and others are highly dependent on several regional markets for revenue generation.


However, the pandemic and the worldwide slowdown have hampered the company's expansion in these areas in 2020. Moreover, several clinical trials for retina health disorders were halted due to pandemic, which further impacted the development of new products. The ophthalmic healthcare services tried to minimize the number of patients attending hospital as medical retina clinics patients are often elderly and have comorbid conditions. Thus, owing to high risk of COVID-19 infection, only high-risk patients for visual loss were being treated. Furthermore, several patients remained reluctant to seek medical attention in the pandemic and deferral of non-urgent medical procedures led to delay and cancellation of orders by many eye care professionals.


Market Dynamics


Drivers


  • Growing prevalence of retinal diseases across the globe


The growing prevalence of retinal diseases including Age-Related Macular Degeneration (AMD), diabetic retinopathy, retinitis pigmentosa, and retinal detachment is one of the major factors driving the retina health market. In addition, the growing incidences of vision impairment and rising myopic population, particularly during the COVID-19 pandemic, have further contributed to the market growth. This is due to the rising usage of screens and joining virtual meetings while working from home leading to the growing prevalence of myopia attributable to an increased risk of various progressive eye disorders such as AMD. In addition rising awareness about the retinal biologics drive the market growth



  • Rising number of strategic initiatives


Restraints



  • Lack of awareness regarding retinal diseases


The lack of awareness regarding symptoms, ignorance, and not seeking timely diagnosis & treatment for retina diseases is anticipated to hamper the market growth. In October 2021, the WHO stated that 2.2 billion people globally suffer from eye impairment. However, nearly half of them could have been prevented by receival of proper treatment on time. The lack is awareness is more in the developing regions of the world where the population is not conditioned to understand eye problems beyond the need to wear glasses.


Value Chain Analysis


The global retina health market is growing at a significant rate and is expected to continue growing at the same rateSome major factors for growth include the growing geriatric population globally and the increasing prevalence of retinal diseases. Moreover, the value chain analysis for the retina health market comprises four major components that start with the research and product development (R&D), followed by the manufacturing of the products, distribution & sales, and ends with post-sales monitoring.


Retina Health Market Segment Overview


The global retina health market has been divided based on treatment and disease indication.


By Treatment


Based on treatment, the market is segmented into drugs, therapy, and surgery.


Global Retina Health Market Share (%), by Treatment, 2021
Retina Health Market Share (%), by Treatment, 2021



  • Drugs


Treatment using medication is considered one of the safest and most economical procedures in treating retinal illness. Moreover, the intake of medicines is effective and is a non-invasive procedure, hence it is opted for by most patients. During the screening and initial phase of the disease, drugs are considered the most prominent way of administering a drug.



  • Therapy


Therapy is a procedure anticipated to cure a disorder by psychological means. The retinal disorders differ in prevalence, diagnosis, and etiology which determines the recommendations related to product development, clinical trial design, and preclinical testing, etc.



  • Surgery


Retinal surgery is one of the frequent OPD processes that is carried out in eye hospitals and centers. The lasers utilized for the surgery are designed to be transmittable through the lens and cornea (non-retinal tissues) without damaging them.


By Disease Indication


Based on disease indication, the global retina health market has been segmented into age-related macular degeneration, diabetic retinopathy, inherited retinal diseases, retinoblastoma, and others.



  • Age-Related Macular Degeneration


Age-related Macular Degeneration (AMD) is an eye illness that affects the center of the field of vision causing irreversible damage specifically among older patients. The factors accelerating the risks include genetic variants, smoking, cardiovascular disease, hypertension, obesity, sun exposure, and a diet with low omega-3 fatty acids and green leafy vegetables.



  • Diabetic Retinopathy


Diabetic retinopathy is a diabetes complication that damages blood vessels in the tissues of the retina. This illness causes vision loss and blindness among people suffering from diabetes. Symptoms diagnosed for diabetic retinopathy involves blurred vision for faraway objects, bleeding of blood vessels in the retina, loss of vision, and floating of black dots across the front of the eye.



  • Inherited Retinal Diseases


Inherited Retinal Diseases are the collection of ailments that results in severe vision loss or even blindness. A few of the inherited retinal disease includes retinitis pigmentosa, rod dystrophy or rod-cone dystrophy, usher syndrome, bietti crystalline dystrophy, Batten disease, Bardet-Biedl syndrome, Alport syndrome, and Leber congenital amaurosis/ early onset retinal dystrophy among others.



  • Retinoblastoma


Retinoblastoma is cancer-related to the retina and caused due to genetic mutations in nerve cells of the retina. The mutation caused uncontrolled cell division of the healthy cells leading to the formation of the accumulation of the mass of cells leading to the tumor.



  • Others


The others segment includes retinal disorders such as retinal tear, and macular holes. A retinal tear is a condition in which the retina faces a tear or has a hole. The progressive wear and tear of the retina lead to a serious medical condition known as a detached retina.


Global Retina Health Market Share (%), by region, 2021 
Retina Health Market Share (%), by region, 2021
Regional Analysis


The global retina health market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World.



  • North America


The North America retina health market is growing due to several factors such as the high prevalence of retinal disorders and the presence of major market players in the region. Moreover, the number of patients with retinal diseases such as dry AMD, retinal vein occlusion, and diabetic eye diseases is steadily increasing in the United States, according to a retrospective study presented during The Association for Research in Vision and Ophthalmology 2020. This study conducted between 2014 and 2019 concluded dry AMD had the largest disease burden over the 6-year period with a 16.3% prevalence.



  • Europe


The European retina health market is growing due to factors like high prevalence of wet AMD, increasing prevalence of diabetes, and presence of a high population of geriatric people. According to a research article published by University of Ljubljana, Ljubljana, Slovenia in September 2019, AMD was responsible for 19.5% and 15.9% of all cases of blindness reported in Eastern Europe and central Europe respectively.



  • Asia-Pacific


The Asia-Pacific (APAC) retina health market is expected to exhibit a strong CAGR of 8.33% during the forecast period from 2022 to 2030 owing to the rapidly improving healthcare infrastructure, increasing per capita income, growing awareness about eye health among the population, and presence of a large geriatric population. For instance, according to the Capital Medical University, Beijing, China in February 2021, it is estimated that South Asia had the highest prevalence of mild vision impairment (12.2%), and moderate to severe vision impairment (17.5%) globally.



  • Rest of the World


The rest of the world comprises the Middle East, Africa, and Latin America. The rest of the world region is expected to register a slower CAGR as compared to other regions owing to presence of poor economies, sub-par healthcare infrastructure, lack of qualified professionals, and lack of public awareness. The region is majorly driven by the developed gulf nations which have well equipped healthcare systems and a high prevalence for retinal disorders as well. Such efforts are expected to drive the market in the region during the forecast period (2022-2030).


Retina Health Market Competitive Landscape


The global retina health market is characterized by the presence of many global, regional, and local players and increasing initiatives by public and private organizations to drive awareness regarding retinal diseases make the retina health market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share.


Key Players


The prominent players in the global retina health market are Novartis AG (Switzerland), Spark Therapeutics, Inc. (Us), Gensight Biologics (France), Allergan Plc (Subsidiary of AbbVie Inc.) (Ireland), Oxford Biomedica Plc (UK), Hemera Biosciences LLC (US), Santen Pharmaceuticals Inc. (Japan), Regenxbio Inc. (US), Meiragtx Limited (US), Applied Genetic Technologies Corporation (AGTC) (US).


Recent Developments



  • In December 2021, Novartis acquired Gyroscope Therapeutics (UK), which focuses on developing gene therapy to treat ailments that affect the eye and lead to vision loss. This acquisition will help the company to gain access to gene therapy and deliver innovation in ophthalmology to treat and prevent blindness worldwide.

  • In September 2021, AbbVie and REGENXBIO Inc. announced a partnership to develop and commercialize RGX-314, potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases.

  • In April 2021, Santen Pharmaceuticals Inc. has established a manufacturing unit in China owing to cater to the increasing demand across this country. This expansion will provide stable eye care product supplies across the country.


Report Overview:


The study covers the existing short-term and long-term market effect, helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in the North America, Europe, Asia-Pacific, and Rest of the World. The report analyzes market drivers, restraints, opportunities, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report & Segmentation


Global Retina Health Market, by Treatment



  • Drugs

  • Therapy

    • Gene Therapy

    • Nutrition Therapy



  • Surgery

  • Others


Global Retina Health Market, by Disease Indication



  • Age-Related Macular Degeneration

  • Diabetic Retinopathy

  • Inherited Retinal Diseases

  • Retinoblastoma

  • Others


Global Retina health market, by Region



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa

    • Latin America





Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 24.22 Billion
  CAGR   7.01%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2018 to 2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Treatment, Disease Indication, Region
  Geographies Covered   North America, Europe, Asia-Pacific, Rest of the World
  Key Vendors   Novartis AG (Switzerland), Spark Therapeutics, Inc. (Us), Gensight Biologics (France), Allergan Plc (Subsidiary Of AbbVie Inc.) (Ireland), Oxford Biomedica Plc (UK), Hemera Biosciences LLC (US), Santen Pharmaceuticals Inc. (Japan), Regenxbio Inc. (US), Meiragtx Limited (US), Applied Genetic Technologies Corporation (AGTC) (US)
  Key Market Opportunities   Increasing initiatives by public and private organizations to drive awareness regarding retinal diseases
  Key Market Drivers   Growing prevalence of retinal diseases across the globe β€’ Rising number of strategic initiatives


Speak to Analyst Ask for Customization